RecruitingNCT06957145

Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation

Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation: A 1-Year Follow-up Study


Sponsor

Koç University

Enrollment

60 participants

Start Date

Jun 30, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies. Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated. Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is examining a specific protein called VISTA on immune cells in people with multiple sclerosis (MS) or a condition that may become MS (called CIS). Researchers want to understand how this immune marker changes over time and whether it relates to how active or severe the disease is — potentially helping develop better treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with MS or clinically isolated syndrome (CIS) based on 2017 McDonald criteria - You do not have any other autoimmune disease or cancer - You are willing to have blood samples taken over a 1-year follow-up **You may NOT be eligible if...** - You have another autoimmune disease or cancer - You are currently using antibiotics, steroids, or other immune-modifying medications that could affect the results - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Koc University

Istanbul, Istanbul, Turkey (Türkiye)

Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic and Neurosurgical Diseases, University of Health Sciences, Istanbul, Turkey

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06957145


Related Trials